Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Brief Reports

Hematocrit and the Incidence of Type 2 Diabetes in the Pima Indians

  1. Marshall K. Tulloch-Reid, MBBS, DSC,
  2. Robert L. Hanson, MD, MPH,
  3. Aramesh Saremi, MD,
  4. Helen C. Looker, MBBS,
  5. Desmond E. Williams, MBCHB, PHD,
  6. Jonathan Krakoff, MD and
  7. William C. Knowler, MD, DRPH
  1. From the Diabetes and Arthritis Epidemiology Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona
  1. Address correspondence to William Knowler, MD, DrPH, Chief, Diabetes and Arthritis Epidemiology Section, National Institutes of Health, 1550 East Indian School Rd., Phoenix, AZ 85014. E-mail: knowler{at}nih.gov
Diabetes Care 2004 Sep; 27(9): 2245-2246. https://doi.org/10.2337/diacare.27.9.2245
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading
  • IGT, impaired glucose tolerance

Several prospective studies have shown that a high hematocrit (or hemoglobin) predicts type 2 diabetes (1–6). However, the reasons for this association have not been fully explored.

Hematocrit has been positively correlated with hyperinsulinemia and conditions associated with insulin resistance such as high blood pressure, elevated serum triglycerides, low HDL cholesterol, and central obesity and could therefore be associated with insulin resistance (7,8). On the other hand, hematocrit is also a major determinant of blood viscosity (9). An elevated blood viscosity is thought to contribute to the development of insulin resistance by reducing blood flow to skeletal muscle, thereby interfering with insulin-mediated glucose uptake in this tissue (10).

The aim of this study was to examine the association between hematocrit and type 2 diabetes incidence in the Pima Indians and to determine whether any association between hematocrit and diabetes incidence was altered by adjustment for fasting insulin.

RESEARCH DESIGN AND METHODS

The population studied was part of an ongoing epidemiological study of diabetes that has been conducted in the Gila River Indian community since 1965 (11). Subjects selected for analysis were ≥20 years old; had height, weight, and hematocrit measurements; and were free of diabetes at their baseline examination. Subjects were classified as nonsmokers, former smokers, and current smokers based on responses to a smoking questionnaire. Hematocrit was measured using an Autocrit centrifuge from venous blood collected in EDTA anticoagulant and stored at 4–10°C until processing. Fasting insulin was measured by radioimmunoassay (Concept 4; ICN Biomedicals, Horsham, PA) in nondiabetic individuals. Diabetes was diagnosed if the 2-h postload glucose from a 75-g oral glucose tolerance test was ≥11.1 mmol/l or if a diagnosis of diabetes had been made during the course of routine medical care because ∼60% of the subjects included in the sample (predominantly subjects with their first examination before 1975) did not have a fasting glucose measurement at their baseline examination. Impaired glucose tolerance (IGT) was defined as a 2-h glucose value of 7.8–11.1 mmol/l after a 75-g oral glucose tolerance test.

Proportional hazards models were used to determine the effect of baseline hematocrit on type 2 diabetes risk. Fasting insulin, waist circumference, HDL cholesterol, and triglycerides were not all routinely measured until 1993. Therefore, a second sample, a subset of the original cohort, was generated. Spearman’s correlation coefficient was used to test the relationship between hematocrit and blood pressure, lipids, waist circumference, and insulin in this subset. Hazard rate ratios (HRRs) and 95% CIs for both cohorts are presented per 5% difference in hematocrit measurements.

RESULTS

A total of 1,286 new cases of type 2 diabetes (480 men and 806 women) were detected in 3,513 subjects (1,489 men and 2,024 women, mean baseline age 30.1 ± 12.4 years, BMI 31.8 ± 9.3 kg/m2, and hematocrit 41.4 ± 4.5%; 15% with IGT) followed over 11 years. Compared with the entire population, the subset with additional measurements (384 men and 609 women) was older, was more obese, had a higher prevalence of IGT, and had a lower mean hematocrit at baseline. One hundred ninety-four new cases of type 2 diabetes (65 men and 129 women) were detected in the subset over an average of 5.2 years.

Hematocrit predicted diabetes after adjustment for age and sex, with an HRR per 5% difference of 1.37 (95% CI 1.26–1.48) in the large cohort (Table 1). The relationship persisted with adjustment for examination date, BMI, cigarette smoking, serum creatinine, and IGT (1.40 [1.28–1.53]). A higher hematocrit increased the risk of type 2 diabetes, even after restricting the analysis to subjects with hematocrit measurements within the normal range (41–53% in men and 36–46% in women).

In the subset, significant correlations were noted between the baseline hematocrit and systolic blood pressure (r = 0.31, P < 0.01), diastolic blood pressure (0.30, P < 0.01), fasting triglycerides (0.18, P < 0.01), and fasting insulin (0.14, P < 0.01). Hematocrit was not correlated with waist circumference (0.04, P = 0.18) and was inversely correlated with HDL cholesterol (−0.07, P = 0.03). The hematocrit was also positively associated with the incidence of type 2 diabetes in this subset, adjusted for age and sex (HRR 1.29 [95% CI 1.02–1.63]); however, with adjustment for fasting insulin, hematocrit no longer predicted diabetes risk (0.97 [0.82–1.15]) (Table 1).

CONCLUSIONS

Hematocrit is correlated with fasting insulin and predicts diabetes incidence in Pima Indians independent of age, sex, BMI, time, serum creatinine, IGT, and cigarette smoking. The effect of hematocrit on diabetes incidence was no longer significant after adjustment for fasting insulin.

Insulin stimulates the proliferation of erythroid progenitor cells in culture (12). In addition, intravenous infusion of insulin increases the transcapillary escape of albumin, thereby reducing the plasma volume and increasing hematocrit (13). Thus a high hematocrit, in the absence of an underlying hematological or medical disorder, may be the result of elevated insulin levels and reflect insulin resistance. We are uncertain as to whether an independent effect might have been noted if plasma viscosity, a measure determined not only by the hematocrit but also by serum proteins (such as fibrinogen and γ-globulins), red cell deformity, and red cell aggregation, had been measured (9).

In conclusion, elevated hematocrit measurements are associated with higher risk of developing type 2 diabetes in the Pima population, possibly mediated through an association with insulin resistance.

View this table:
  • View inline
  • View popup
Table 1—

HRRs (with 95% CIs) for the development of type 2 diabetes per 5% difference in blood hematocrit

Acknowledgments

We thank the members of the Gila River Indian Community and all the staff at the National Institutes of Health Clinic in Sacaton. We also thank Dr. Robert Nelson for his advice and comments on the manuscript.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted June 15, 2004.
    • Received May 14, 2004.
  • DIABETES CARE

References

  1. ↵
    Medalie JH, Papier CM, Goldbourt U, Herman JB: Major factors in the development of diabetes mellitus in 10,000 men. Arch Intern Med 135:811–817, 1975
    OpenUrlCrossRefPubMedWeb of Science
  2. Wilson PW, McGee DL, Kannel WB: Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham Study. Am J Epidemiol 114:697–704, 1981
    OpenUrlAbstract/FREE Full Text
  3. Wannamethee SG, Perry IJ, Shaper AG: Hematocrit and risk of NIDDM. Diabetes 45:576–579, 1996
    OpenUrlAbstract/FREE Full Text
  4. Burchfiel CM, Curb JD, Rodriguez BL, Yano K, Hwang LJ, Fong KO, Marcus EB: Incidence and predictors of diabetes in Japanese-American men: the Honolulu Heart Program. Ann Epidemiol 5:33–43, 1995
    OpenUrlCrossRefPubMed
  5. Tamariz L, Young H, Pankow J, Schmidt M, Yeh HABBF: Blood Viscosity is a risk factor for incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study (ARIC) (Abstract). Diabetes 52 (Suppl. 1):A230, 2003
    OpenUrl
  6. ↵
    Nakanishi N, Suzuki K, Tatara K: Haematocrit and risk of development of type 2 diabetes mellitus in middle-aged Japanese men. Diabet Med 21:476–482, 2004
    OpenUrlCrossRefPubMed
  7. ↵
    Barbieri M, Ragno E, Benvenuti E, Zito GA, Corsi A, Ferrucci L, Paolisso G: New aspects of the insulin resistance syndrome: impact on haematological parameters. Diabetologia 44:1232–1237, 2001
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Wannamethee G, Perry IJ, Shaper AG: Haematocrit, hypertension and risk of stroke. J Intern Med 235:163–168, 1994
    OpenUrl
  9. ↵
    MacRury SM, Lowe GD: Blood rheology in diabetes mellitus. Diabet Med 7:285–291, 1990
    OpenUrlPubMedWeb of Science
  10. ↵
    Baron AD, Steinberg H, Brechtel G, Johnson A: Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am J Physiol 266:E248–E253, 1994
  11. ↵
    Bennett PH, Burch TA, Miller M: Diabetes mellitus in American (Pima) Indians. Lancet 2:125–128, 1971
    OpenUrlPubMedWeb of Science
  12. ↵
    Bersch N, Groopman JE, Golde DW: Natural and biosynthetic insulin stimulates the growth of human erythroid progenitors in vitro. J Clin Endocrinol Metab 55:1209–1211, 1982
    OpenUrlCrossRefPubMed
  13. ↵
    Hilsted J, Christensen NJ: Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia 35:99–103, 1992
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 27 (9)

In this Issue

September 2004, 27(9)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hematocrit and the Incidence of Type 2 Diabetes in the Pima Indians
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hematocrit and the Incidence of Type 2 Diabetes in the Pima Indians
Marshall K. Tulloch-Reid, Robert L. Hanson, Aramesh Saremi, Helen C. Looker, Desmond E. Williams, Jonathan Krakoff, William C. Knowler
Diabetes Care Sep 2004, 27 (9) 2245-2246; DOI: 10.2337/diacare.27.9.2245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Hematocrit and the Incidence of Type 2 Diabetes in the Pima Indians
Marshall K. Tulloch-Reid, Robert L. Hanson, Aramesh Saremi, Helen C. Looker, Desmond E. Williams, Jonathan Krakoff, William C. Knowler
Diabetes Care Sep 2004, 27 (9) 2245-2246; DOI: 10.2337/diacare.27.9.2245
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL Cholesterol
  • β-Cell Transplantation Restores Metabolic Control and Quality of Life in a Patient With Subcutaneous Insulin Resistance
Show more Brief Reports

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.